| |  Online-Ressource |
|---|
| Verfasst von: | Stoll, Felicitas E. [VerfasserIn]  |
|---|
| | Seidel-Glätzer, Andrea [VerfasserIn] |
|---|
| | Burghaus, Ina [VerfasserIn] |
|---|
| | Göring, Oliver [VerfasserIn] |
|---|
| | Sauter, Max [VerfasserIn] |
|---|
| | Rose, Peter [VerfasserIn] |
|---|
| | Daniel, Volker [VerfasserIn] |
|---|
| | Haag, Mathias [VerfasserIn] |
|---|
| | Schwab, Matthias [VerfasserIn] |
|---|
| | Riffel, Johannes [VerfasserIn] |
|---|
| | André, Florian [VerfasserIn] |
|---|
| | Taylor, Lenka A. [VerfasserIn] |
|---|
| | Weiß, Johanna [VerfasserIn] |
|---|
| | Burhenne, Jürgen [VerfasserIn] |
|---|
| | Cleeves, Volker [VerfasserIn] |
|---|
| | Haefeli, Walter E. [VerfasserIn] |
|---|
| | Blank, Antje [VerfasserIn] |
|---|
| Titel: | Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide |
|---|
| Titelzusatz: | n exploratory phase I clinical trial |
|---|
| Verf.angabe: | Felicitas Stoll, Andrea Seidel-Glätzer, Ina Burghaus, Oliver Göring, Max Sauter, Peter Rose, Volker Daniel, Mathias Haag, Matthias Schwab, Johannes Riffel, Florian André, Lenka Taylor, Johanna Weiss, Jürgen Burhenne, Volker Cleeves, Walter E. Haefeli and Antje Blank |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 14 December 2022 |
|---|
| Umfang: | 16 S. |
|---|
| Fussnoten: | Gesehen am 21.02.2023 |
|---|
| Titel Quelle: | Enthalten in: International journal of molecular sciences |
|---|
| Ort Quelle: | Basel : Molecular Diversity Preservation International, 2000 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 23(2022), 24, Artikel-ID 15924, Seite 1-16 |
|---|
| ISSN Quelle: | 1422-0067 |
|---|
| | 1661-6596 |
|---|
| Abstract: | Bile acids (BA) play an important role in cholesterol metabolism and possess further beneficial metabolic effects as signalling molecules. Blocking the hepatocellular uptake of BA via sodium-taurocholate co-transporting polypeptide (NTCP) with the first-in-class drug bulevirtide, we expected to observe a decrease in plasma LDL cholesterol. In this exploratory phase I clinical trial, volunteers with LDL cholesterol > 130 mg/dL but without overt atherosclerotic disease were included. Thirteen participants received bulevirtide 5 mg/d subcutaneously for 12 weeks. The primary aim was to estimate the change in LDL cholesterol after 12 weeks. Secondary endpoints included changes in total cholesterol, HDL cholesterol, lipoprotein(a), inflammatory biomarkers, and glucose after 12 weeks. In addition, cardiac magnetic resonance imaging (CMR) was performed at four time points. BA were measured as biomarkers of the inhibition of hepatocellular uptake. |
|---|
| DOI: | doi:10.3390/ijms232415924 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/ijms232415924 |
|---|
| | Volltext: https://www.mdpi.com/1422-0067/23/24/15924 |
|---|
| | DOI: https://doi.org/10.3390/ijms232415924 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | bile acid |
|---|
| | bulevirtide |
|---|
| | LDL cholesterol |
|---|
| | NTCP |
|---|
| | phase I clinical trial |
|---|
| K10plus-PPN: | 1837214387 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Metabolic effect of blocking sodium-taurocholate co-transporting polypeptide in hypercholesterolemic humans with a twelve-week course of bulevirtide / Stoll, Felicitas E. [VerfasserIn]; 14 December 2022 (Online-Ressource)
